Bibliographic Details
| Title: |
Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment |
| Document Number: |
20100254991 |
| Publication Date: |
October 7, 2010 |
| Appl. No: |
12/817432 |
| Application Filed: |
June 17, 2010 |
| Abstract: |
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. |
| Inventors: |
Kastelein, Robert A. (Portola Valley, CA, US); McClanahan, Terrill K. (Sunnyvale, CA, US); Murphy, Erin (Mountain View, CA, US); Chan, Jason R. (Palo Alto, CA, US) |
| Assignees: |
Schering Corporation (Kenilworth, NJ, US), Schering Corporation (Kenilworth, NJ, US), Schering Corporation (Kenilworth, NJ, US), Schering Corporation (Kenilworth, NJ, US) |
| Claim: |
1. A method of evaluating the propensity of a subject to develop an inflammatory skin disorder comprising: a) obtaining a sample of skin from the subject; and b) quantifying the level of IL-17 or IL-19 expression in the sample. |
| Claim: |
2. The method of claim 1, wherein the IL-17 or IL-19 expression is mRNA expression. |
| Claim: |
3. The method of claim 1, wherein the level of IL-17 or IL-19 expression is quantified by real-time PCR. |
| Claim: |
4. The method of claim 1, wherein the inflammatory skin disorder is cutaneous inflammation. |
| Claim: |
5. The method of claim 4, wherein the cutaneous inflammation is psoriasis. |
| Claim: |
6. The method of claim 1, wherein the skin sample is from both lesional and non-lesional psoriatic skin. |
| Claim: |
7. The method of claim 6, wherein the level of IL-17 expression in the skin sample is an average value between 5 and 20 fold higher than normal skin. |
| Claim: |
8. The method of claim 6, wherein the level of IL-19 expression in the skin sample is an average value of between 5 and 130 fold higher than normal skin. |
| Claim: |
9. The method of claim 1, wherein the subject has: a) a family history of psoriasis; or b) previously presented psoriatic symptoms. |
| Claim: |
10. The method of claim 1, wherein the subject is a human. |
| Claim: |
11. A method of preventing skin inflammation comprising administering to a subject exhibiting a propensity to develop skin inflammation: a) an antagonist of IL-17; b) an antagonist of IL-23; c) an antagonist of IL-19; or c) an antagonist of at least two cytokines selected from the group consisting of IL-17, IL-19, and IL-23. |
| Claim: |
12. The method of claim 11, wherein the skin inflammation is cutaneous inflammation. |
| Claim: |
13. The method of claim 11, wherein the cutaneous inflammation is psoriasis. |
| Claim: |
14. The method of claim 11, wherein the subject expresses an average value of at least 5 fold higher IL-17 expression in a non-lesional psoriatic skin sample compared to a normal skin sample, as quantified by real-time PCR. |
| Claim: |
15. The method of claim 11, wherein the subject expresses an average value of at least 20 fold higher IL-19 expression in a non-lesional psoriatic skin sample compared to a normal skin sample as quantified by real-time PCR. |
| Claim: |
16. The method of claim 11, wherein the antagonist of IL-17, IL-19, and/or IL-23 is an: a) antibody or binding fragment thereof; b) siRNA; or c) a small molecule inhibitor. |
| Claim: |
17. The method of claim 16, wherein the antibody is: a) a polyclonal antibody; b) a monoclonal antibody; c) a humanized antibody; d) a bi-specific antibody. |
| Current U.S. Class: |
4241/361 |
| Current International Class: |
61; 61; 61; 12 |
| Accession Number: |
edspap.20100254991 |
| Database: |
USPTO Patent Applications |
